The “6th Edition of Cardiology World Conference” (Cardio 2025) takes place in London, UK and Virtually, from September 15-17, 2025.
The conference, with its overarching theme of “Advancing Heart Health: Breakthroughs in Cardiology” covers a comprehensive range of topics, including cardiovascular diseases and disorders, advanced imaging techniques such as echocardiography and cardiac MRI, and innovative treatments for heart failure and myocardial infarction.
Relaxera’s CEO Thomas Bernd Dschietzig is giving a keynote presentation, titled
“The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF”
The presentation provides animal study data about relaxin-2 reversing left atrial enlargement, fibrosis and DD. In summary, hRlx-2 is highly effective as a candidate therapy for HFpEF. A phase-II clinical trial in HFpEF/HFmrEF patients will start in late 2025.